Psoriasis Treatment Breakthrough: Secukinumab Rapidly Reduces Joint Inflammation
Secukinumab, a monoclonal antibody targeting interleukin-17A, significantly reduces subclinical joint inflammation in patients diagnosed with psoriasis. Recent clinical data confirms that this biologic therapy targets the underlying systemic immune response ... Read More